276 related articles for article (PubMed ID: 10741861)
21. The role of Th1 and Th2 cells for mucosal IgA responses.
Yamamoto M; Vancott JL; Okahashi N; Marinaro M; Kiyono H; Fujihashi K; Jackson RJ; Chatfield SN; Bluethmann H; McGhee JR
Ann N Y Acad Sci; 1996 Feb; 778():64-71. PubMed ID: 8611017
[TBL] [Abstract][Full Text] [Related]
22. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1.
Romeu B; González E; Del Campo J; Acevedo R; Zayas C; Valdés Y; Cabrera O; Cuello M; Balboa J; Lastre M; Pérez O
Can J Microbiol; 2011 Mar; 57(3):256-61. PubMed ID: 21358768
[TBL] [Abstract][Full Text] [Related]
23. Mucosal Vaccination With Recombinant
Wei J; Hegde VL; Yanamandra AV; O'Hara MP; Keegan B; Jones KM; Strych U; Bottazzi ME; Zhan B; Sastry KJ; Hotez PJ
Front Immunol; 2022; 13():800295. PubMed ID: 35197976
[TBL] [Abstract][Full Text] [Related]
24. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
[TBL] [Abstract][Full Text] [Related]
25. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.
Marinaro M; Staats HF; Hiroi T; Jackson RJ; Coste M; Boyaka PN; Okahashi N; Yamamoto M; Kiyono H; Bluethmann H; Fujihashi K; McGhee JR
J Immunol; 1995 Nov; 155(10):4621-9. PubMed ID: 7594461
[TBL] [Abstract][Full Text] [Related]
26. The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity.
Xu L; Tudor D; Bomsel M
Front Immunol; 2020; 11():599278. PubMed ID: 33613520
[TBL] [Abstract][Full Text] [Related]
27. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation.
Jones HP; Hodge LM; Fujihashi K; Kiyono H; McGhee JR; Simecka JW
J Immunol; 2001 Oct; 167(8):4518-26. PubMed ID: 11591779
[TBL] [Abstract][Full Text] [Related]
28. Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.
Yue Y; Xu W; Xiong S
DNA Cell Biol; 2012 Apr; 31(4):479-88. PubMed ID: 21988406
[TBL] [Abstract][Full Text] [Related]
29. The ocular conjunctiva as a mucosal immunization route: a profile of the immune response to the model antigen tetanus toxoid.
Barisani-Asenbauer T; Inic-Kanada A; Belij S; Marinkovic E; Stojicevic I; Montanaro J; Stein E; Bintner N; Stojanovic M
PLoS One; 2013; 8(4):e60682. PubMed ID: 23637758
[TBL] [Abstract][Full Text] [Related]
30. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.
Hoft DF; Eickhoff CS
Infect Immun; 2002 Dec; 70(12):6715-25. PubMed ID: 12438346
[TBL] [Abstract][Full Text] [Related]
31. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.
Yamamoto M; McGhee JR; Hagiwara Y; Otake S; Kiyono H
Scand J Immunol; 2001 Mar; 53(3):211-7. PubMed ID: 11251876
[TBL] [Abstract][Full Text] [Related]
32. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery.
Arulanandam BP; Metzger DW
Vaccine; 1999 Jan; 17(3):252-60. PubMed ID: 9987161
[TBL] [Abstract][Full Text] [Related]
33. Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen.
Barnes AG; Cerovic V; Hobson PS; Klavinskis LS
Eur J Immunol; 2007 Jun; 37(6):1538-47. PubMed ID: 17474150
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity.
Kim E; Attia Z; Woodfint RM; Zeng C; Kim SH; Steiner HE; Shukla RK; Liyanage NPM; Ghimire S; Li J; Renukaradhya GJ; Satoskar AR; Amer AO; Liu SL; Cormet-Boyaka E; Boyaka PN
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34353890
[TBL] [Abstract][Full Text] [Related]
35. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.
Hagiwara Y; McGhee JR; Fujihashi K; Kobayashi R; Yoshino N; Kataoka K; Etani Y; Kweon MN; Tamura S; Kurata T; Takeda Y; Kiyono H; Fujihashi K
J Immunol; 2003 Feb; 170(4):1754-62. PubMed ID: 12574339
[TBL] [Abstract][Full Text] [Related]
36. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response.
Bliss J; Van Cleave V; Murray K; Wiencis A; Ketchum M; Maylor R; Haire T; Resmini C; Abbas AK; Wolf SF
J Immunol; 1996 Feb; 156(3):887-94. PubMed ID: 8558014
[TBL] [Abstract][Full Text] [Related]
37. New perspectives in vaccine development: mucosal immunity to infections.
McGhee JR; Kiyono H
Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
[TBL] [Abstract][Full Text] [Related]
38. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.
Chow YH; Chiang BL; Lee YL; Chi WK; Lin WC; Chen YT; Tao MH
J Immunol; 1998 Feb; 160(3):1320-9. PubMed ID: 9570550
[TBL] [Abstract][Full Text] [Related]
39. Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts.
Singh UP; Singh S; Ravichandran P; Taub DD; Lillard JW
J Immunol; 2004 Nov; 173(9):5509-16. PubMed ID: 15494499
[TBL] [Abstract][Full Text] [Related]
40. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
